导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 6.51% | 1135/4775 |
| 近一周 | -1.40% | 2412/5468 |
| 近一月 | 0.46% | 2384/5401 |
| 近一季 | -3.99% | 1980/5193 |
| 近半年 | 2.44% | 1552/4905 |
| 近一年 | 11.81% | 1607/4330 |
| 近两年 | 45.38% | 1628/2947 |
| 近三年 | 29.52% | 990/2226 |
| 成立以来 | 127.34% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
0.86% 1425/4961 |
14.03% 1890/5312 |
- - |
- - |
| 2025 | 16.57% 2442/4813 |
-1.11% 2582/3635 |
1.62% 2261/4076 |
14.87% 2862/4524 |
0.98% 1620/4813 |
| 2024 | 13.24% 1161/3463 |
-0.03% 1063/2808 |
1.03% 510/3014 |
13.75% 2115/3129 |
-1.43% 1698/3463 |
| 2023 | -6.18% 821/2656 |
3.15% 1251/2280 |
-2.43% 590/2385 |
-2.23% 643/2515 |
-4.66% 1132/2655 |
| 2022 | -22.87% 1096/2207 |
-15.40% 1037/1919 |
4.41% 1017/2016 |
-14.20% 1046/2113 |
1.77% 1152/2208 |
| 2021 | -0.62% 756/1822 |
-2.41% 636/1255 |
8.26% 641/1330 |
-6.44% 930/1466 |
0.54% 1093/1822 |
| 2020 | 58.23% 137/1250 |
-3.52% 303/1028 |
20.02% 287/1067 |
16.75% 136/1164 |
17.03% 140/1184 |
| 2019 | 42.66% 210/1092 |
27.00% 365/754 |
0.42% 172/804 |
1.62% 380/850 |
10.07% 166/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 西部利得沪深300指数增强C VS. 长安沪深300非周期A(740101) |